Non-alcoholic fatty liver (NAFLD) is the most common liver disease worldwide, progressing
from simple steatosis to necroinflammation and fibrosis (leading to non-alcoholic …

Hypercholesterolemia is a frequent metabolic disorder associated with increased risk for
cardiovascular morbidity and mortality. In addition to its well‐known proatherogenic effect …

Background Long-term statin treatment reduces the frequency of cardiovascular events, but
safety and efficacy in patients with abnormal liver tests is unclear. We assessed whether …

The focus of this review is on the role of apolipoprotein C-II (apoC-II) in lipoprotein
metabolism and the potential effects on the risk of cardiovascular disease (CVD). We …

Background: Sexual dysfunction affects millions of people with an increasing prevalence,
worldwide. The pathophysiology of the disease shares several similarities with …

Objectives To evaluate the effectiveness of long-term treatment of statins for chronic
obstructive pulmonary disease (COPD), and to answer which one is better. Methods General …

Non‐alcoholic fatty liver disease (NAFLD) encompasses a spectrum of disease ranging from
simple steatosis through steatohepatitis (NASH) to increasing fibrosis and eventual cirrhosis …

Objective Nonalcoholic fatty liver disease (NAFLD) is the most frequent cause of elevated
transaminase levels and affects approximately one third of the general population. Patients …

Results Among participants, 326 had modestly elevated LFTs and ultrasonographic (US)
evidence of NAFLD (165 patients in group A2 and 161 patients in group B2). The NAFLD …

Objective To investigate and analyse the existing evidence supporting statin therapy in
patients with lower limb atherosclerotic arterial disease. Methods A systematic search of …